Simon TA, Suissa S, Skovron ML, Frisell T, Askling J, Michaud K, Pedro S, Strangfeld A, Meissner Y, Boers M, Hoffman V, Dominique A, Gomez A, Hochberg MC. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2024 Feb;64:152313. doi: 10.1016/j.semarthrit.2023.152313
Park EM, Tan X, Stephenson EM, Deal AM, Yopp JM, Rosenstein DL, Edwards T, Song MK. Psychometric analysis of the parenting concerns questionnaire in women with metastatic cancer. J Pain Symptom Manage. 2018 Feb;55(2):451-7. doi: 10.1016/j.jpainsymman.2017.09.021
Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach. Semin Arthritis Rheum. 2014 Aug;44(1):39-46. doi: 10.1016/j.semarthrit.2014.03.001
Thyagarajan (Hoffman) V, Norman H, Alexander KA, Napalkov P, Enger C. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients. Semin Arthritis Rheum. 2012 Dec;42(3):223-33. doi: 10.1016/j.semarthrit.2012.05.004
Williams VSL, Smith M, Fehnel SE. The validity and utility of the BPI interference measures for evaluating the impact of osteoarthritic pain. J Pain Symptom Manage. 2006 Jan 1;31(1):48-57.
Neighbors DM, Bell TJ, Wilson J, Dodd SL. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001 Feb 1;21(2):129-43. doi: 10.1016/s0885-3924(00)00247-5.
Neighbors DM, Dodd SL. Re: economic evaluation of fentanyl - Response. J Pain Symptom Manage. 2001 Jan 1;22(1):541-3.